Assessment of Early Growth Response 1 in Tumor Suppression of Esophageal Squamous Cell Carcinoma

Background: Esophageal squamous cell carcinoma (ESCC) is associated with poor survival despite surgical resection, and its pathogenesis has been broadly investigated in the past decade. Early growth response 1 (EGR-1) could involve regulating tumor development in ESCC cells. Methods: An attempt was made to examine the molecular and cellular influence of EGR-1 in esophageal cancer cells by RNA extraction, real-time PCR (qRT-PCR), cell culture, small interfering RNA (siRNA) knockdown, western blot, migration assay, and cell viability assay. One hundred and forty-four samples of ESCC were collected from our hospital and analyzed. Significantly higher EGR-1 expression was noted in tumor-adjacent normal tissue compared with tumor lesions. Results: The univariate analysis showed no significant impacts of EGR-1 expression on patients’ survival. However, after adjusting for the pathological stage, patients with EGR-1 expression > 68th percentile had lower risks of cancer-related death. Moreover, knockdown of EGR-1 significantly enhanced cell migration, invasion, and resistance to chemotherapeutic agents in two ESCC cell lines. Conclusions: EGR-1 plays a key role in tumor suppression involving tumor viability suppression and reflects the treatment effect of current chemotherapy for ESCC.

[1]  Md. Saiful Islam,et al.  Prognostic role of EGR1 in breast cancer: a systematic review , 2021, BMB reports.

[2]  Darui Wang,et al.  Egr‑1 inhibits colon cancer cell proliferation, migration and invasion via regulating CDKL1 at the transcriptional level. , 2021, Oncology reports.

[3]  T. Sunkara,et al.  Epidemiology of esophageal cancer: update in global trends, etiology and risk factors , 2020, Clinical Journal of Gastroenterology.

[4]  Wei Zhang,et al.  miRNA-181a-5p Enhances the Sensitivity of Cells to Cisplatin in Esophageal Adenocarcinoma by Targeting CBLB , 2020, Cancer management and research.

[5]  Wanhai Xu,et al.  EGR1 Regulates Angiogenic and Osteoclastogenic Factors in Prostate Cancer and Promotes Metastasis , 2019, Oncogene.

[6]  Ling Lin,et al.  TCF7L2 and EGR1 synergistic activation of transcription of LCN2 via an ERK1/2-dependent pathway in esophageal squamous cell carcinoma cells. , 2019, Cellular signalling.

[7]  Kangdong Liu,et al.  α-solanine enhances the chemosensitivity of esophageal cancer cells by inducing microRNA‑138 expression. , 2018, Oncology reports.

[8]  K. Liang,et al.  Overexpression of miR-191 Predicts Poor Prognosis and Promotes Proliferation and Invasion in Esophageal Squamous Cell Carcinoma , 2017, Yonsei medical journal.

[9]  Kunming Zhao,et al.  EGR-1/ASPP1 inter-regulatory loop promotes apoptosis by inhibiting cyto-protective autophagy , 2017, Cell Death & Disease.

[10]  Chi Zhang,et al.  A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. , 2017, Oncology reports.

[11]  Dongqing Wang,et al.  Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis. , 2017, Molecular and clinical oncology.

[12]  Zhao-lu Kong,et al.  Upregulating DAB2IP expression via EGR-1 inhibition, a new approach for overcoming fractionated-irradiation-induced cross-tolerance to ionizing radiation and mitomycin C in tumor cells , 2017, International journal of radiation biology.

[13]  L. Lan,et al.  Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727. , 2017, Oncology reports.

[14]  D. Pei,et al.  Egr-1 suppresses breast cancer cells proliferation by arresting cell cycle progression via down-regulating CyclinDs. , 2017, International journal of clinical and experimental pathology.

[15]  A. Shelling,et al.  A novel EGR‐1 dependent mechanism for YB‐1 modulation of paclitaxel response in a triple negative breast cancer cell line , 2016, International journal of cancer.

[16]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[17]  H. Hsu,et al.  The 4E-BP1/eIF4E ratio is a determinant for rapamycin response in esophageal cancer cells. , 2015, The Journal of thoracic and cardiovascular surgery.

[18]  Su-Hyung Hong,et al.  Early growth response protein 1 upregulation and nuclear translocation by 2'-benzoyloxycinnamaldehyde induces prostate cancer cell death. , 2013, Cancer letters.

[19]  P. Leung,et al.  Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells , 2013, Oncogene.

[20]  E. Parra,et al.  The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines. , 2010, Oncology reports.

[21]  Na Xu,et al.  Hypoxia Stabilizes Microtubule Networks and Decreases Tumor Cell Chemosensitivity to Anticancer Drugs Through Egr‐1 , 2010, Anatomical record.

[22]  W. Hsu,et al.  Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. , 2008, The Journal of thoracic and cardiovascular surgery.

[23]  F. Wamunyokoli,et al.  A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. , 2006, Cancer research.

[24]  D. Mercola,et al.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin , 2006, Cancer Gene Therapy.

[25]  Dan Mercola,et al.  Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. , 2005, Cancer research.

[26]  Huan-Xing Yang,et al.  Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. , 2004, World journal of gastroenterology.

[27]  A. Porcellini,et al.  The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  P. Humphrey,et al.  Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. , 2001, Human pathology.

[29]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[30]  D. Tindall,et al.  Expression of early growth response genes in human prostate cancer. , 1998, Cancer research.

[31]  D. Mercola,et al.  Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation , 1997, International journal of cancer.

[32]  R. Figlin,et al.  Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. , 1995, Oncogene.

[33]  H. Takano,et al.  Different sensitivities of human esophageal cancer cells to multiple anti‐cancer agents and related mechanisms , 1992, Cancer.